StreetInsider.com News Articles

Form 10-Q Rapport Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26870325.html

Form 10-Q Rapport Therapeutics, For: Jun 30

Wed, 05 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26870325.html

Form 8-K Rapport Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870247.html

Form 8-K Rapport Therapeutics, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870247.html

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Wed, 05 Aug 2026 07:00:00 -0400

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients

RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026

Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine

Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029

BOSTON and SAN DIEGO,

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Wed, 05 Aug 2026 07:00:00 -0400

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients

RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026

Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine

Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029

BOSTON and SAN DIEGO,

Form 4 Rapport Therapeutics, For: Jul 27 Filed by: Ceesay Abraham

Wed, 29 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260729/26834864.html

Form 4 Rapport Therapeutics, For: Jul 27 Filed by: Ceesay Abraham

Wed, 29 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260729/26834864.html

William Blair Starts Rapport Therapeutics (RAPP) at Outperform

Mon, 27 Jul 2026 16:07:59 -0400

William Blair analyst Myles Minter initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Outperform rating.

The analyst comments "We are initiating coverage of Rapport Therapeutics with an Outperform rating and fair value of $79.03 per share. Rapport is a clinical-stage leader in developing therapies targeting receptor-associated proteins (RAPs) and is focused on treating neurology and neuropsychiatry disorders of high unmet clinical need. Risks are primarily clinical, regulatory, and commercial in nature, similar to other biotechnology companies."

For an analyst ratings summary and ratings history on Rapport Therapeutics click here. For more ratings news on Rapport Therapeutics click here.

Shares of

William Blair Starts Rapport Therapeutics (RAPP) at Outperform

Mon, 27 Jul 2026 16:07:59 -0400

William Blair analyst Myles Minter initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Outperform rating.

For an analyst ratings summary and ratings history on Rapport Therapeutics click here. For more ratings news on Rapport Therapeutics click here.

Shares of

Form 4 Rapport Therapeutics, For: Jul 14 Filed by: Ceesay Abraham

Wed, 15 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260715/26774328.html

Form 4 Rapport Therapeutics, For: Jul 14 Filed by: Ceesay Abraham

Wed, 15 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260715/26774328.html

Form 4 Rapport Therapeutics, For: Jun 30 Filed by: Gault Cheryl

Wed, 01 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260701/26720716.html

Form 4 Rapport Therapeutics, For: Jun 30 Filed by: Gault Cheryl

Wed, 01 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260701/26720716.html

Form 4 Rapport Therapeutics, For: Jun 29 Filed by: Ceesay Abraham

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720589.html

Form 4 Rapport Therapeutics, For: Jun 29 Filed by: Ceesay Abraham

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720589.html

Form 144 Rapport Therapeutics, Filed by: Gault Cheryl

Tue, 30 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260630/26714183.html

Form 144 Rapport Therapeutics, Filed by: Gault Cheryl

Tue, 30 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260630/26714183.html

Form 144 Rapport Therapeutics, Filed by: Ceesay Abraham

Mon, 29 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260629/26707186.html

Form 144 Rapport Therapeutics, Filed by: Ceesay Abraham

Mon, 29 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260629/26707186.html

Leerink Starts Rapport Therapeutics (RAPP) at Outperform

Wed, 24 Jun 2026 06:22:59 -0400

(Updated - June 24, 2026 6:22 AM EDT)

Leerink analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Outperform rating and a price target of $52.00.

The analyst commented: "We are initiating coverage of RAPP with an Outperform rating and a sum-of-the-parts (SOTP)-based $52 PT. Our investment thesis is the following: We like the epilepsy market; companies are utilizing fast mover development strategies, translation from preclinical models to humans is predictable, physicians like to try new therapies and/or novel MoAs, polypharmacy is prevalent with patients often on multiple drugs and payer pushback is relatively low since patients are refractive

Leerink Starts Rapport Therapeutics (RAPP) at Outperform

Wed, 24 Jun 2026 06:22:59 -0400

(Updated - June 24, 2026 6:22 AM EDT)

Leerink analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ: RAPP) with a Outperform rating and a price target of $52.00.

Form 4 Rapport Therapeutics, For: Jun 10 Filed by: MARAGANORE JOHN

Wed, 10 Jun 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260610/26631070.html

Form 4 Rapport Therapeutics, For: Jun 10 Filed by: MARAGANORE JOHN

Wed, 10 Jun 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260610/26631070.html

Form 4 Rapport Therapeutics, For: Jun 10 Filed by: PEREZ ROBERT J

Wed, 10 Jun 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260610/26631059.html